Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Keytruda (pembrolizumab; Merck & Co) Drug Analysis 2016-2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Keytruda" drug pipelines has been added to ResearchAndMarkets.com's offering.

Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor.

The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival and induces apoptosis of tumor-specific T cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.

It has also been hypothesized that blocking the PD-1/PD-L1 interactions releases the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.

Key Topics Covered:

Product Profiles

  1. Colorectal cancer (CRC)
  2. Head and neck cancer
  3. Hepatocellular carcinoma (HCC)
  4. Bladder cancer
  5. Renal cell cancer (RCC)
  6. Non-small cell lung cancer (NSCLC)
  7. NHL: Diffuse large B-cell lymphoma (DLBCL)
  8. Gastric cancer
  9. Breast cancer: triple-negative
  10. Melanoma
  11. Multiple myeloma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hjj8x8/keytruda?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006177/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.